文献速递神经核医学肿瘤 PET/CT放射性药物与辐射防护

深度学习增强真实超低剂量淀粉样蛋白PET/MRI用于临床解读

True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-08

该研究纳入18名参与者,分别进行超低剂量(6.64 ± 3.57 MBq,为标准剂量的2.2 ± 1.3%)和标准剂量(300 ± 14 MBq)的18F-florbetaben PET/MRI检查,并利用预训练卷积神经网络结合MRI进行图像增强。结果显示增强后图像质量指标显著改善,所有增强图像非劣于标准剂量,淀粉样蛋白状态分类准确率高(注入超低剂量增强图像97.2%,采样超低剂量增强图像91.7%),表明深度学习可从真实超低注射剂量PET/MRI数据合成诊断质量图像。

要点

  • 深度学习增强可显著改善真实超低剂量淀粉样PET/MRI的图像质量指标。
  • 增强图像在主观质量评分上非劣于标准剂量图像。
  • 淀粉样蛋白状态分类准确率高达97.2%(注入超低剂量增强图像)。

核心结论

  • 深度学习方法可从真实超低注射剂量的同步PET/MRI数据合成诊断质量的PET图像。
  • 研究验证了采样超低剂量实现的普遍有效性,并表明淀粉样蛋白成像可显著降低剂量。

研究设计与样本

  • 前瞻性研究纳入18名参与者,每人接受两次18F-florbetaben PET/MRI:超低剂量(6.64 ± 3.57 MBq,为标准剂量的2.2 ± 1.3%)和标准剂量(300 ± 14 MBq)。
  • 标准剂量列表模式数据经欠采样模拟超低剂量;预训练卷积神经网络使用MRI和注入或采样超低剂量PET进行微调。

主要发现

  • 深度学习增强PET图像在所有质量指标(峰值信噪比、结构相似性、均方根误差)上较低剂量图像显著改善,区域CV与标准剂量总体相似。
  • 所有增强图像非劣于对应的标准剂量图像(采用15%非劣效界值,评分≥3分的比例)。
  • 淀粉样蛋白状态分类准确率:注入超低剂量增强图像97.2%,采样超低剂量增强图像91.7%,与标准剂量图像读者内可重复性(98.6%)相近。

关键数值与推荐

  • 主观图像质量采用五点量表评分,非劣效界值为评分≥3分的比例差异不超过15%。
  • 淀粉样蛋白状态分类准确率以注入超低剂量增强图像97.2%、采样超低剂量增强图像91.7%为关键数值。

临床怎么用

  • 对于淀粉样蛋白PET/MRI,深度学习增强可支持使用真实超低注射剂量(约标准剂量的2.2%)获得诊断质量图像。
  • 临床解读时可参考增强图像的淀粉样蛋白状态分类高准确率,但需注意本研究样本量有限。

局限性

  • 样本量较小(18名参与者)。
  • 研究仅针对18F-florbetaben淀粉样蛋白PET/MRI,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While sampled or short-frame realizations have shown the potential power of deep learning to reduce radiation dose for PET images, evidence in true injected ultra-low-dose cases is lacking. Therefore, we evaluated deep learning enhancement using a significantly reduced injected radiotracer protocol for amyloid PET/MRI. METHODS: Eighteen participants underwent two separate 18F-florbetaben PET/MRI studies in which an ultra-low-dose (6.64 ± 3.57 MBq, 2.2 ± 1.3% of standard) or a standard-dose (300 ± 14 MBq) was injected. The PET counts from the standard-dose list-mode data were also undersampled to approximate an ultra-low-dose session. A pre-trained convolutional neural network was fine-tuned using MR images and either the injected or sampled ultra-low-dose PET as inputs. Image quality of the enhanced images was evaluated using three metrics (peak signal-to-noise ratio, structural similarity, and root mean square error), as well as the coefficient of variation (CV) for regional standard uptake value ratios (SUVRs). Mean cerebral uptake was correlated across image types to assess the validity of the sampled realizations. To judge clinical performance, four trained readers scored image quality on a five-point scale (using 15% non-inferiority limits for proportion of studies rated 3 or better) and classified cases into amyloid-positive and negative studies. RESULTS: The deep learning-enhanced PET images showed marked improvement on all quality metrics compared with the low-dose images as well as having generally similar regional CVs as the standard-dose. All enhanced images were non-inferior to their standard-dose counterparts. Accuracy for amyloid status was high (97.2% and 91.7% for images enhanced from injected and sampled ultra-low-dose data, respectively) which was similar to intra-reader reproducibility of standard-dose images (98.6%). CONCLUSION: Deep learning methods can synthesize diagnostic-quality PET images from ultra-low injected dose simultaneous PET/MRI data, demonstrating the general validity of sampled realizations and the potential to reduce dose significantly for amyloid imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen KT, Toueg TN, Koran MEI, et al. True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation. Eur J Nucl Med Mol Imaging. 2021. PMID: 33416955. doi:10.1007/s00259-020-05151-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。